Arrhythmia Alliance News & Events
Don't let cancelled/postponed conferences stop your educational learning! We have a large number of educational presentations available online HERE
Identify patients with Atrial Fibrillation
Thousands of people with Atrial Fibrillation are not being diagnosed because doctors are pushed for time and are not carrying out simple pulse checks, says Professor Camm, professor of clinical cardiology based at St George’s, University of London, and an international renowned expert in atrial fibrillation. He is also President of Arrhythmia Alliance and a Trustee of AF Association.
Free Pulse Checks for Londoners during Global AF Awareness Week
More than 150,0000 Londoners have the most common type of irregular heartbeat, which is called Atrial Fibrillation or AF, and are at higher risk of a stroke. Not everyone with AF has symptoms and a simple pulse rhythm check could save their life.
NELFT and North East London Local Pharmaceutical Committee have won an award
NELFT and North East London Local Pharmaceutical Committee have been announced as one of the ‘AF Association Healthcare Pioneers 2018 – Showcasing Best Practice in AF’ winners.
Atrial fibrillation: What sufferers need to know to slash their risks of having a stroke
It's Global Atrial Fibrillation Awareness Week. Here's everything you need to know.
ONE IN THREE PEOPLE WITH AF ARE UNDIAGNOSED AND AT INCREASED RISK OF SUFFERING AN
Monday 20 November 2017, London: Today is the launch of AF Association Global AF Aware Week (20-26 November), with over 1,000 events taking place across the UK to help identify the undiagnosed person with AF (atrial fibrillation). More than half a million people in the UK currently have undiagnosed AF which leaves them at increased risk of suffering a debilitating, life-threatening AF-related stroke – the most severe type of stroke.
AF ASSOCIATION NAMES WINNERS OF PRESTIGIOUS UK HEALTHCARE PIONEER AWARDS
Heart Rhythm Congress, ICC, Birmingham: Trudie Lobban, Founder and CEO, AF Association announced this year’s winners of the AF Association “UK Healthcare Pioneers 2018 – Showcasing Best Practice in AF” at the Arrhythmia Alliance Awards Ceremony.
AF CAUSES ONE THIRD OF ALL STROKES – THESE CAN BE PREVENTED, THIS SCANDAL CANNOT BE ALLOWED TO CONTINUE
Many of the world’s leading authorities on the management and treatment of atrial fibrillation (AF) met at the Heart Rhythm Congress to present the case for perfecting the care of AF patients: Detect AF by a simple pulse check; perfect against AF-related stroke using anticoagulation therapy, not aspirin; and correct the irregular heart rhythm with access to appropriate treatment.
Wearable Technology: Safeguards will help boost sales
This month Apple claimed that its much-feted, but reportedly under-selling, Apple Watch had saved lives. In one case a 62-year-old builder felt terrible after lunch. His watch had revealed an abnormally high pulse and he called an ambulance. Doctors were said to have told him that he might have died if he had gone straight home. This is a good news story, but medical specialists fear that it may create a misleading impression about the accuracy of personal pulse checkers in hand-held monitors and smartphones.
INTERNATIONAL HEART RHYTHM CONGRESS CALLS FOR URGENT ACTION TO PREVENT THOUSANDS OF UNNECESSARY DEATHS FROM ARRHYTHMIAS..
Over 3,000 heart rhythm specialists and healthcare professionals from around the world are arriving in Birmingham for the annual Heart Rhythm Congress (HRC), starting on Sunday (1-4 October), the UK’s largest educational congress devoted solely to arrhythmias (heart rhythm disorders).
PATIENT DIES AFTER BEING DENIED ACCESS TO LIFE-SAVING TREATMENT DUE TO LACK OF NHS FUNDING
Arrhythmia Alliance is calling on NHS England to reconsider its ‘Commissioning through Evaluation’ (CtE) process, following the death of a high risk atrial fibrillation (AF) patient from a bleed to the brain after being refused a potentially life-saving treatment. The evaluation process of left atrial appendage occlusion (LAAO), a treatment approved by the FDA and used across Europe, has meant hundreds of patients being denied access to this treatment with no guarantee when the evaluation will be completed to allow access.